Novo Nordisk A/S (NYSE:NVO)

55.18
Delayed Data
As of Jul 02
 -0.26 / -0.47%
Today’s Change
41.72
Today|||52-Week Range
58.21
+30.39%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$110.7B

Company Description

Novo Nordisk AS engages in the research, development, manufacture, and marketing of pharmaceutical products. It operates through the Diabetes Care and Biopharmaceuticals segments. The Diabetes Care segment deals with the research, development, manufacture, and marketing of products within the areas of insulin, glucagon-like-peptide 1 and related delivery systems, oral anti-diabetic products, and obesity. The Biopharmaceuticals segment handles the research, development, manufacture, and distribution of products within the areas of haemophilia, growth hormone, hormone replacement, inflammation and other therapy areas. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Contact Information

Novo Nordisk A/S
Novo Allé
Gladsaxe Capital Region 2880
P:(454) 444-8888
Investor Relations:
(609) 235-8567

Employees

Shareholders

Other institutional6.80%
Mutual fund holders2.92%
Individual stakeholders--

Top Executives

Lars Rebien SørensenChief Executive Officer
KÃ¥re SchultzPresident & Chief Operating Officer
Jesper BrandgaardChief Financial Officer & Executive Vice President
Mads Krogsgaard ThomsenChief Science Officer & Executive Vice President
Alan C. MosesGlobal Chief Medical Officer

To view my watchlist

Not a member yet?

Sign up now for a free account